

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Yorimasa SUWA et al.

Application No.: 10/569,791

Confirmation No.: 6478

Filed: February 27, 2006

Art Unit: N/A

For: TARGET PROTEIN OF ANTIDIABETIC AND
NOVEL ANTIDIABETIC "INSUFUL"
CORRESPONDING THERETO

Examiner: Not Yet Assigned

RESPONSE TO NOTICE TO COMPLY

MS Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

On October 3, 2006 the U.S. Patent and Trademark Office mailed to Applicant's representative a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. To comply, submitted herewith is the required paper and disk copy of the Sequence Listing and necessary amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for

Application No.: 10/569,791

Docket No.: 1254-0305PUS1

any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: December 1, 2006

Respectfully submitted,

By 

Gerald M. Murphy, Jr.

Registration No.: 28,977

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road

Suite 100 East

P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant

Attachments: Amendment with paper and disk copy of Sequence Listing and copy of Notice to Comply